Published in J Virol on May 07, 2014
The Role of Gammaherpesviruses in Cancer Pathogenesis. Pathogens (2016) 0.83
The Microbiome, Systemic Immune Function, and Allotransplantation. Clin Microbiol Rev (2016) 0.79
Epstein-Barr Virus: Diseases Linked to Infection and Transformation. Front Microbiol (2016) 0.78
Establishing and characterizing a new primary effusion lymphoma cell line harboring Kaposi's sarcoma-associated herpesvirus. Infect Agent Cancer (2016) 0.77
Valpromide Inhibits Lytic Cycle Reactivation of Epstein-Barr Virus. MBio (2016) 0.76
Rapidly progressive Kaposi's Sarcoma in an Iraqi boy received Valproic acid: a case report and review of literature. BMC Pediatr (2016) 0.75
ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res (2011) 14.51
Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med (1996) 12.11
Persisting oncogenic herpesvirus induced by the tumour promotor TPA. Nature (1978) 9.25
Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci U S A (1985) 8.19
Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem (2001) 6.85
A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A (1998) 6.76
Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut (1987) 6.61
Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein. Virology (1998) 5.43
A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J Virol (1988) 5.28
Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae. J Virol (1996) 5.05
Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells. J Virol (1997) 4.45
New Epstein-Barr virus variants from cellular subclones of P3J-HR-1 Burkitt lymphoma. Nature (1982) 4.43
Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji). J Natl Cancer Inst (1966) 4.19
Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J Virol (1987) 4.12
Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1. J Virol (1990) 4.09
Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology (1979) 4.02
Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. N Engl J Med (1996) 3.61
Kaposi's sarcoma-associated herpesvirus open reading frame 50/Rta protein activates the entire viral lytic cycle in the HH-B2 primary effusion lymphoma cell line. J Virol (2000) 3.50
Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int J Cancer (1984) 3.49
Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Proc Natl Acad Sci U S A (1996) 3.13
The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J Virol (1998) 2.84
An Epstein-Barr virus-producer line Akata: establishment of the cell line and analysis of viral DNA. Virus Genes (1991) 2.77
The effect of sodium butyrate on histone modification. Cell (1978) 2.73
Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. J Virol (1991) 2.58
Epstein-Barr virus lytic replication elicits ATM checkpoint signal transduction while providing an S-phase-like cellular environment. J Biol Chem (2004) 1.86
Different accessibilities in chromatin to histone acetylase. J Biol Chem (1979) 1.79
Chromatin remodeling of the Kaposi's sarcoma-associated herpesvirus ORF50 promoter correlates with reactivation from latency. J Virol (2003) 1.70
Role of the epstein-barr virus RTA protein in activation of distinct classes of viral lytic cycle genes. J Virol (1999) 1.66
Histone acetylation and reactivation of Epstein-Barr virus from latency. J Virol (2000) 1.64
Reactivation of Epstein-Barr virus from latency. Rev Med Virol (2005) 1.58
A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood (2006) 1.57
Acetylation of the latency-associated nuclear antigen regulates repression of Kaposi's sarcoma-associated herpesvirus lytic transcription. J Virol (2006) 1.57
Early activation of the Kaposi's sarcoma-associated herpesvirus RTA, RAP, and MTA promoters by the tetradecanoyl phorbol acetate-induced AP1 pathway. J Virol (2004) 1.51
A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol (2010) 1.50
Butyrate and propionate: important components of toxic dental plaque extracts. Infect Immun (1981) 1.43
Alteration of a single serine in the basic domain of the Epstein-Barr virus ZEBRA protein separates its functions of transcriptional activation and disruption of latency. J Virol (1997) 1.35
ZEB1 regulates the latent-lytic switch in infection by Epstein-Barr virus. PLoS Pathog (2007) 1.33
Clinical and experimental applications of sodium phenylbutyrate. Drugs R D (2011) 1.32
Activation of the Epstein-Barr virus genome by 5-aza-cytidine in latently infected human lymphoid lines. Int J Cancer (1981) 1.32
Early events in Epstein-Barr virus genome expression after activation: regulation by second messengers of B cell activation. Virology (1991) 1.29
Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res (2006) 1.28
Activation of the BRLF1 promoter and lytic cycle of Epstein-Barr virus by histone acetylation. Nucleic Acids Res (2000) 1.28
Identification of a negative cis element within the ZII domain of the Epstein-Barr virus lytic switch BZLF1 gene promoter. J Virol (1998) 1.28
Kaposi's sarcoma-associated herpesvirus ori-Lyt-dependent DNA replication: dual role of replication and transcription activator. J Virol (2006) 1.26
Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle. J Virol (2002) 1.23
Apoptotic death in adenocarcinoma cell lines induced by butyrate and other histone deacetylase inhibitors. Biochem Pharmacol (1997) 1.20
An Sp1 response element in the Kaposi's sarcoma-associated herpesvirus open reading frame 50 promoter mediates lytic cycle induction by butyrate. J Virol (2005) 1.19
Valproic acid induces human herpesvirus 8 lytic gene expression in BCBL-1 cells. AIDS (2000) 1.17
Induction of Epstein-Barr virus lytic cycle by tumor-promoting and non-tumor-promoting phorbol esters requires active protein kinase C. J Virol (1991) 1.14
Monitoring octanoic and decanoic acids in plasma from children with intractable epilepsy treated with medium-chain triglyceride diet. Clin Chem (1982) 1.11
Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors. J Virol (2009) 1.10
Cohesins repress Kaposi's sarcoma-associated herpesvirus immediate early gene transcription during latency. J Virol (2012) 1.08
Identification of a novel element involved in regulation of the lytic switch BZLF1 gene promoter of Epstein-Barr virus. J Virol (2001) 1.08
Relationship between herpesviruses and adult periodontitis and periodontopathic bacteria. J Periodontol (1999) 1.04
The cellular ataxia telangiectasia-mutated kinase promotes epstein-barr virus lytic reactivation in response to multiple different types of lytic reactivation-inducing stimuli. J Virol (2012) 1.03
Composition of pooled resting plaque fluid from caries-free and caries-susceptible individuals. J Dent Res (1988) 1.00
Effect of n-butyrate on cellular and viral DNA synthesis in cells latently infected with Epstein-Barr virus. Virology (1980) 0.99
Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells. J Virol (2012) 0.99
Cells lytically infected with Epstein-Barr virus are detected and separable by immunoglobulins from EBV-seropositive individuals. J Virol Methods (2006) 0.97
Dynamic chromatin environment of key lytic cycle regulatory regions of the Epstein-Barr virus genome. J Virol (2011) 0.95
Signaling cascades triggered by bacterial metabolic end products during reactivation of Kaposi's sarcoma-associated herpesvirus. J Virol (2007) 0.94
Expression of Epstein-Barr virus BZLF1 immediate-early protein induces p53 degradation independent of MDM2, leading to repression of p53-mediated transcription. Virology (2009) 0.93
Medium-chain fatty acids: functional lipids for the prevention and treatment of the metabolic syndrome. Pharmacol Res (2009) 0.91
Critical role of p53 in histone deacetylase inhibitor-induced Epstein-Barr virus Zta expression. J Virol (2008) 0.91
Targeting human herpesvirus-8 for treatment of Kaposi's sarcoma and primary effusion lymphoma. Curr Opin Oncol (2005) 0.88
Herpesviruses 6, 7 and 8 in HIV- and non-HIV-associated periodontitis. J Periodontal Res (2000) 0.87
Molecular and clinical assessment in the treatment of AIDS Kaposi sarcoma with valproic Acid. Clin Infect Dis (2009) 0.87
Valproic acid antagonizes the capacity of other histone deacetylase inhibitors to activate the Epstein-barr virus lytic cycle. J Virol (2011) 0.87
Effects of n-butyrate and phorbol ester (TPA) on induction of Epstein-Barr virus antigens and cell differentiation. Arch Virol (1984) 0.87
The Epstein-Barr virus BRRF1 protein, Na, induces lytic infection in a TRAF2- and p53-dependent manner. J Virol (2011) 0.86
Stimulus duration and response time independently influence the kinetics of lytic cycle reactivation of Epstein-Barr virus. J Virol (2009) 0.86
Shutoff of BZLF1 gene expression is necessary for immortalization of primary B cells by Epstein-Barr virus. J Virol (2012) 0.86
Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity. Int J Lab Hematol (2009) 0.85
Inhibitory effects of resveratrol on the Epstein-Barr virus lytic cycle. Molecules (2010) 0.84
A novel approach for nasopharyngeal carcinoma treatment uses phenylbutyrate as a protein kinase C modulator: implications for radiosensitization and EBV-targeted therapy. Clin Cancer Res (2000) 0.82
Dietary therapies for epilepsy: future research. Epilepsy Behav (2011) 0.82
p53 and Sp1 cooperate to regulate the expression of Epstein-Barr viral Zta protein. J Med Virol (2012) 0.81
Phenylbutyrate induces cell differentiation and modulates Epstein-Barr virus gene expression in Burkitt's lymphoma cells. Clin Cancer Res (1999) 0.81
Could valerian have been the first anticonvulsant? Epilepsia (2004) 0.80
Cancer chemopreventive effects of polyunsaturated fatty acids. Cancer Lett (2004) 0.78
Inhibition of the Epstein-Barr virus lytic cycle by moronic acid. Antiviral Res (2009) 0.78
Effect of short-chain fatty acids on Epstein-Barr virus early and viral capsid antigen induction in P3HR-1 cells. Cancer Lett (1980) 0.77
Quantitative analysis of the Epstein-Barr virus-inducing properties of short-chain fatty acids present in the culture fluids of oral bacteria. Arch Virol (1991) 0.76
Activation of Epstein-Barr virus expression in human lymphoblastoid P3HR-1 and Raji cells with propionic acid and with culture fluids of propionic acid-producing anaerobes. Cancer Lett (1982) 0.76
Pilot study of sodium phenylbutyrate as adjuvant in cyclophosphamide-resistant endemic Burkitt's lymphoma. Trans R Soc Trop Med Hyg (2007) 0.76
Valpromide Inhibits Lytic Cycle Reactivation of Epstein-Barr Virus. MBio (2016) 0.76